T
20.23
0.28 (1.40%)
| 前收盘价格 | 19.95 |
| 收盘价格 | 20.05 |
| 成交量 | 1,841,624 |
| 平均成交量 (3个月) | 1,849,895 |
| 市值 | 1,796,521,088 |
| 价格/销量 (P/S) | 7.11 |
| 股市价格/股市净资产 (P/B) | 31.56 |
| 52周波幅 | |
| 利润日期 | 30 Jul 2025 - 4 Aug 2025 |
| 营业毛利率 | -137.90% |
| 营业利益率 (TTM) | -79.34% |
| 稀释每股收益 (EPS TTM) | -4.07 |
| 季度收入增长率 (YOY) | 66.00% |
| 总债务/股东权益 (D/E MRQ) | 679.76% |
| 流动比率 (MRQ) | 2.08 |
| 营业现金流 (OCF TTM) | -237.48 M |
| 杠杆自由现金流 (LFCF TTM) | -228.53 M |
| 资产报酬率 (ROA TTM) | -23.15% |
| 股东权益报酬率 (ROE TTM) | -246.75% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看跌 |
| Biotechnology (全球的) | 混合的 | 看跌 | |
| 股票 | Travere Therapeutics, Inc. | 看跌 | 看涨 |
AIStockmoo 评分
0.3
| 分析师共识 | 2.0 |
| 内部交易活动 | NA |
| 价格波动 | -0.5 |
| 技术平均移动指标 | -2.5 |
| 技术振荡指标 | 2.0 |
| 平均 | 0.25 |
|
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 0.63% |
| 机构持股比例 | 109.23% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 47.00 (Canaccord Genuity, 132.33%) | 购买 |
| 47.00 (Guggenheim, 132.33%) | 购买 | |
| 中 | 35.00 (73.01%) | |
| 低 | 23.00 (Stifel, 13.69%) | 保留 |
| 平均值 | 36.71 (81.46%) | |
| 总计 | 6 购买, 1 保留 | |
| 平均价格@调整类型 | 18.51 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Stifel | 02 May 2025 | 23.00 (13.69%) | 保留 | 20.76 |
| Wedbush | 02 May 2025 | 30.00 (48.29%) | 购买 | 20.76 |
| Guggenheim | 14 Apr 2025 | 47.00 (132.33%) | 购买 | 14.83 |
| Canaccord Genuity | 10 Apr 2025 | 47.00 (132.33%) | 购买 | 13.49 |
| B of A Securities | 01 Apr 2025 | 31.00 (53.24%) | 购买 | 17.44 |
| JP Morgan | 26 Feb 2025 | 44.00 (117.50%) | 购买 | 21.03 |
| Citigroup | 24 Feb 2025 | 35.00 (73.01%) | 购买 | 21.23 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合